Immix Biopharma, Inc.
IMMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | -0.18 | 0.06 | -0.00 |
| FCF Yield | -25.35% | -9.52% | -24.45% | -3.38% |
| EV / EBITDA | -2.02 | -6.35 | -2.05 | -1.22 |
| Quality | ||||
| ROIC | -158.58% | -99.78% | -60.35% | -7.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.73 | 0.90 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -38.07% | -54.20% | -365.90% | -292.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 1.09 | 1.64 | 0.73 |
| Interest Coverage | 0.00 | 0.00 | -16,537.12 | -7.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |